Triple GIP/GLP-1/Glucagon Receptor Agonist2 mgInvestigational

2 mg Retatrutide Dosage Calculator

Convert your 2 mg retatrutide escalation dose to precise units based on your vial concentration.

Retatrutide is an investigational medication currently in clinical trials. It has not been approved by the FDA for any indication.

050100

How many units is 2 mg of Retatrutide at 2 mg/mL?

Draw

100units

1.00 mL on a U-100 insulin syringe

2 mg ÷ 2 mg/mL × 100 = 100 units

This dose exceeds 50 units (0.5 mL). Volumes greater than 0.5 mL may be uncomfortable for subcutaneous injection. Consult your provider about splitting the dose into two injections.

For educational purposes only. Always follow your provider's instructions.

Quick Reference Table

All dose × concentration combinations

Dose2 mg/mL5 mg/mL10 mg/mL
1 mg502010
2 mg100*4020
4 mg200*80*40
8 mg400*160*80*
12 mg600*240*120*

Values in U-100 insulin syringe units

* Exceeds 50 units (0.5 mL) — may require splitting into two injections

There's an easier way

Tired of calculating doses?

We handle everything — the prescription, the right dose, and shipping straight to your door. No math, no hassle.

Get Started

2-min quiz · Free consultation · No commitment

About the 2 mg Dose

The 2 mg dose is the first escalation step in the retatrutide clinical trial protocol, used during weeks 5 through 8. Patients move to this dose after completing the 1 mg initiation phase. As a triple-receptor agonist targeting GIP, GLP-1, and glucagon receptors, retatrutide at 2 mg begins to produce more noticeable appetite suppression and metabolic effects.

Frequently Asked Questions

In a 2 mg/mL vial, 2 mg retatrutide equals 100 units. The math is (2 / 2) x 100 = 100 units. In a 5 mg/mL vial, it would be 40 units, and in a 10 mg/mL vial, it would be 20 units.

The 2 mg dose is used during weeks 5 through 8 of the Phase 2 clinical trial protocol. It follows the 1 mg initiation dose and precedes the 4 mg escalation at week 9. This step doubles the starting dose to begin establishing therapeutic drug levels while monitoring for tolerability.

Phase 2 trial data showed that gastrointestinal side effects including nausea, diarrhea, and decreased appetite were the most common at all retatrutide doses. At 2 mg, these effects were generally mild and transient. The gradual titration from 1 mg to 2 mg helped minimize the severity of these reactions compared to starting at higher doses.

While both are early escalation doses, direct comparison is premature since retatrutide is still in clinical trials. Retatrutide's unique glucagon receptor activity in addition to GIP and GLP-1 agonism may contribute to additional energy expenditure and fat metabolism. However, firm efficacy comparisons will require head-to-head trials that have not yet been conducted.

Other Retatrutide Doses

1 mg Retatrutide4 mg Retatrutide8 mg Retatrutide12 mg Retatrutide

Related Pages

Retatrutide CalculatorRetatrutide Dosing

Ready to Get Started?

Take our 2-minute quiz to see if you qualify for GLP-1 treatment.

Start Quiz

Free consultation. No commitment.